$ABBV Q2 2026:
Revenue: $16.99B vs. $16.81B expected
Revenue growth: +10.2%
Adjusted EPS: $3.65 vs. $3.64 expected
GAAP EPS: $2.03 vs. $0.52 last year
Adjusted operating margin: 48.3%
The main story was immunology.
Global immunology revenue rose 15.1% to $8.79B.
Skyrizi revenue increased 24.4% to $5.51B.
Rinvoq revenue increased 24.5% to $2.53B.
Humira revenue fell 35.9% to $756M.
That shows AbbVie’s post-Humira transition is still being carried by Skyrizi and Rinvoq.
Neuroscience also grew strongly.
Revenue rose 20.3% to $3.23B, helped by Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and Vyalev.
Oncology was mixed.
Venclexta and Elahere grew, while Imbruvica declined 29.4%.
Aesthetics was nearly flat, with Botox Cosmetic up 5.2% and Juvederm down 6.0%.
AbbVie also announced its planned $10.9B acquisition of Apogee Therapeutics to expand its immunology pipeline.
Full-year adjusted EPS guidance was updated to $13.87 to $14.07, slightly below the prior range due to expected Apogee deal dilution.
[https://www.prnewswire.com/news-releases/abbvie-reports-second-quarter-2026-financial-results-302839981.html](https://www.prnewswire.com/news-releases/abbvie-reports-second-quarter-2026-financial-results-302839981.html)